Genmab — Januar 2026
-
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma
Yahoo Finance (finance.yahoo.com)
-
For the Dutch : Dr. Marcel Nijland over epcoritamab met R2 bij R/R folliculair lymfoom https://www.mednet.nl/congres-nieuws/dr-marcel-nijland-over-epcoritamab-met-r2-bij-r-r-folliculair-lymfoom/
-
https://ir.genmab.com/news-releases/news-release-details/genmab-announces-topline-results-epcoritamab-duobodyr-cd3xcd20 Genmab Announces Topline Results for Epcoritamab (DuoBody
CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) -
OS indeed disappoints -on the first look. we all know though during what period this trial was conducted, and analysis will have to show how disappointing it really is, or if Covid circumstances led to this result, and other therapies after controll arm relapse which could be a factor...
-
Truist maintains optimism for 2026 read-out after Genmab’s Phase 3 trial OS miss https://www.tipranks.com/news/the-fly/truist-maintains-optimism-for-2026-read-out-after-genmabs-phase-3-trial-os-miss-thefly#google_vignette
-
Truist notes Genmab (GMAB) reported Phase 3 results from the EPCORE DLBCL-1 trial in transplant-ineligible second-line positive diffuse large B-cell lymphoma patients. The study missed its overall survival endpoint. However, this outcome does not change the firm’s view on the key frontline DLBCL study, and Truist remains optimistic for a positive read-out this year. The firm has a Buy rating on the shares with a price target of $48.
-
Fra Børsen "Og studiet peger ifølge Genmab på en forbedring af den progressionsfri overlevelse, når Epcoritamab blev anvendt som monoterapi.
“Derudover blev der observeret forbedringer i den komplette responsrate, responsvarigheden og tiden til næste behandling blandt patienter, der blev behandlet med Epcoritamab som monoterapi,” skriver Genmab i en meddelelse.
Det er ifølge Genmab det første fase 3-studie til dato, der har vist en forbedret progressionsfri overlevelse i patienter med
???Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind